From protein degradation to 'toad venom': Another five biotechs will make the Nasdaq shuffle after filing SEC paperwork
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Friday proved to be another busy day for biotech IPOs, with five more companies filing their S-1s and F-1s with the SEC ahead of expected jumps to Nasdaq.
Four biotechs penciled in initial estimates of $100 million raises: protein-degradation player Monte Rosa, gene editing biotech Graphite Bio, “toad venom”-focused GH Research and monoclonal antibody developer Elevation Oncology. The fifth company, reagents provider Alpha Teknova, estimates at least $75 million with their raise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.